BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 26589479)

  • 1. Raf/ERK drives the proliferative and invasive phenotype of BMPR2-silenced pulmonary artery endothelial cells.
    Awad KS; Elinoff JM; Wang S; Gairhe S; Ferreyra GA; Cai R; Sun J; Solomon MA; Danner RL
    Am J Physiol Lung Cell Mol Physiol; 2016 Jan; 310(2):L187-201. PubMed ID: 26589479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CCL5 deficiency rescues pulmonary vascular dysfunction, and reverses pulmonary hypertension via caveolin-1-dependent BMPR2 activation.
    Nie X; Tan J; Dai Y; Liu Y; Zou J; Sun J; Ye S; Shen C; Fan L; Chen J; Bian JS
    J Mol Cell Cardiol; 2018 Mar; 116():41-56. PubMed ID: 29374556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BMPR2 Loss Activates AKT by Disrupting DLL4/NOTCH1 and PPARγ Signaling in Pulmonary Arterial Hypertension.
    Awad KS; Wang S; Dougherty EJ; Keshavarz A; Demirkale CY; Yu ZX; Miller L; Elinoff JM; Danner RL
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Codependence of Bone Morphogenetic Protein Receptor 2 and Transforming Growth Factor-β in Elastic Fiber Assembly and Its Perturbation in Pulmonary Arterial Hypertension.
    Tojais NF; Cao A; Lai YJ; Wang L; Chen PI; Alcazar MAA; de Jesus Perez VA; Hopper RK; Rhodes CJ; Bill MA; Sakai LY; Rabinovitch M
    Arterioscler Thromb Vasc Biol; 2017 Aug; 37(8):1559-1569. PubMed ID: 28619995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dysregulated Smooth Muscle Cell BMPR2-ARRB2 Axis Causes Pulmonary Hypertension.
    Wang L; Moonen JR; Cao A; Isobe S; Li CG; Tojais NF; Taylor S; Marciano DP; Chen PI; Gu M; Li D; Harper RL; El-Bizri N; Kim YM; Stankunas K; Rabinovitch M
    Circ Res; 2023 Mar; 132(5):545-564. PubMed ID: 36744494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-Muscle MLCK Contributes to Endothelial Cell Hyper-Proliferation through the ERK Pathway as a Mechanism for Vascular Remodeling in Pulmonary Hypertension.
    Anis M; Gonzales J; Halstrom R; Baig N; Humpal C; Demeritte R; Epshtein Y; Jacobson JR; Fraidenburg DR
    Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endothelin-Bone morphogenetic protein type 2 receptor interaction induces pulmonary artery smooth muscle cell hyperplasia in pulmonary arterial hypertension.
    Maruyama H; Dewachter C; Belhaj A; Rondelet B; Sakai S; Remmelink M; Vachiery JL; Naeije R; Dewachter L
    J Heart Lung Transplant; 2015 Mar; 34(3):468-78. PubMed ID: 25447587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of bone morphogenetic protein receptor 2 is associated with abnormal DNA repair in pulmonary arterial hypertension.
    Li M; Vattulainen S; Aho J; Orcholski M; Rojas V; Yuan K; Helenius M; Taimen P; Myllykangas S; De Jesus Perez V; Koskenvuo JW; Alastalo TP
    Am J Respir Cell Mol Biol; 2014 Jun; 50(6):1118-28. PubMed ID: 24433082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physiologic and molecular consequences of endothelial Bmpr2 mutation.
    Majka S; Hagen M; Blackwell T; Harral J; Johnson JA; Gendron R; Paradis H; Crona D; Loyd JE; Nozik-Grayck E; Stenmark KR; West J
    Respir Res; 2011 Jun; 12(1):84. PubMed ID: 21696628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenotypically Silent Bone Morphogenetic Protein Receptor 2 Mutations Predispose Rats to Inflammation-Induced Pulmonary Arterial Hypertension by Enhancing the Risk for Neointimal Transformation.
    Tian W; Jiang X; Sung YK; Shuffle E; Wu TH; Kao PN; Tu AB; Dorfmüller P; Cao A; Wang L; Peng G; Kim Y; Zhang P; Chappell J; Pasupneti S; Dahms P; Maguire P; Chaib H; Zamanian R; Peters-Golden M; Snyder MP; Voelkel NF; Humbert M; Rabinovitch M; Nicolls MR
    Circulation; 2019 Oct; 140(17):1409-1425. PubMed ID: 31462075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytoskeletal defects in Bmpr2-associated pulmonary arterial hypertension.
    Johnson JA; Hemnes AR; Perrien DS; Schuster M; Robinson LJ; Gladson S; Loibner H; Bai S; Blackwell TR; Tada Y; Harral JW; Talati M; Lane KB; Fagan KA; West J
    Am J Physiol Lung Cell Mol Physiol; 2012 Mar; 302(5):L474-84. PubMed ID: 22180660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of MicroRNA-124 as a Major Regulator of Enhanced Endothelial Cell Glycolysis in Pulmonary Arterial Hypertension via PTBP1 (Polypyrimidine Tract Binding Protein) and Pyruvate Kinase M2.
    Caruso P; Dunmore BJ; Schlosser K; Schoors S; Dos Santos C; Perez-Iratxeta C; Lavoie JR; Zhang H; Long L; Flockton AR; Frid MG; Upton PD; D'Alessandro A; Hadinnapola C; Kiskin FN; Taha M; Hurst LA; Ormiston ML; Hata A; Stenmark KR; Carmeliet P; Stewart DJ; Morrell NW
    Circulation; 2017 Dec; 136(25):2451-2467. PubMed ID: 28971999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PTPN1 Deficiency Modulates BMPR2 Signaling and Induces Endothelial Dysfunction in Pulmonary Arterial Hypertension.
    Ali MK; Tian X; Zhao L; Schimmel K; Rhodes CJ; Wilkins MR; Nicolls MR; Spiekerkoetter EF
    Cells; 2023 Jan; 12(2):. PubMed ID: 36672250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endothelial
    Theilmann AL; Hawke LG; Hilton LR; Whitford MKM; Cole DV; Mackeil JL; Dunham-Snary KJ; Mewburn J; James PD; Maurice DH; Archer SL; Ormiston ML
    Arterioscler Thromb Vasc Biol; 2020 Nov; 40(11):2605-2618. PubMed ID: 32998516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autophagy contributes to BMP type 2 receptor degradation and development of pulmonary arterial hypertension.
    Gomez-Puerto MC; van Zuijen I; Huang CJ; Szulcek R; Pan X; van Dinther MA; Kurakula K; Wiesmeijer CC; Goumans MJ; Bogaard HJ; Morrell NW; Rana AA; Ten Dijke P
    J Pathol; 2019 Nov; 249(3):356-367. PubMed ID: 31257577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tenascin-C is induced by mutated BMP type II receptors in familial forms of pulmonary arterial hypertension.
    Ihida-Stansbury K; McKean DM; Lane KB; Loyd JE; Wheeler LA; Morrell NW; Jones PL
    Am J Physiol Lung Cell Mol Physiol; 2006 Oct; 291(4):L694-702. PubMed ID: 16782755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defective cellular trafficking of the bone morphogenetic protein receptor type II by mutations underlying familial pulmonary arterial hypertension.
    John A; Kizhakkedath P; Al-Gazali L; Ali BR
    Gene; 2015 Apr; 561(1):148-56. PubMed ID: 25688877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bmpr2 Mutant Rats Develop Pulmonary and Cardiac Characteristics of Pulmonary Arterial Hypertension.
    Hautefort A; Mendes-Ferreira P; Sabourin J; Manaud G; Bertero T; Rucker-Martin C; Riou M; Adão R; Manoury B; Lambert M; Boet A; Lecerf F; Domergue V; Brás-Silva C; Gomez AM; Montani D; Girerd B; Humbert M; Antigny F; Perros F
    Circulation; 2019 Feb; 139(7):932-948. PubMed ID: 30586714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BMPRII influences the response of pulmonary microvascular endothelial cells to inflammatory mediators.
    Vengethasamy L; Hautefort A; Tielemans B; Belge C; Perros F; Verleden S; Fadel E; Van Raemdonck D; Delcroix M; Quarck R
    Pflugers Arch; 2016 Nov; 468(11-12):1969-1983. PubMed ID: 27816994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dysregulated zinc and sphingosine-1-phosphate signaling in pulmonary hypertension: Potential effects by targeting of bone morphogenetic protein receptor type 2 in pulmonary microvessels.
    Tran HB; Maiolo S; Harper R; Zalewski PD; Reynolds PN; Hodge S
    Cell Biol Int; 2021 Nov; 45(11):2368-2379. PubMed ID: 34347342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.